JP6047172B2 - 患者部分集団における痛風の治療方法 - Google Patents

患者部分集団における痛風の治療方法 Download PDF

Info

Publication number
JP6047172B2
JP6047172B2 JP2014541012A JP2014541012A JP6047172B2 JP 6047172 B2 JP6047172 B2 JP 6047172B2 JP 2014541012 A JP2014541012 A JP 2014541012A JP 2014541012 A JP2014541012 A JP 2014541012A JP 6047172 B2 JP6047172 B2 JP 6047172B2
Authority
JP
Japan
Prior art keywords
uric acid
gout
subject
compound
oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014541012A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014532759A5 (OSRAM
JP2014532759A (ja
Inventor
ゴパール・チャンドラ・サハ
ブライアン・ケイ・ロバーツ
ブライアン・エドワード・ラバン
チャールズ・エイ・マックウェーター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CymaBay Therapeutics Inc
Original Assignee
CymaBay Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CymaBay Therapeutics Inc filed Critical CymaBay Therapeutics Inc
Publication of JP2014532759A publication Critical patent/JP2014532759A/ja
Publication of JP2014532759A5 publication Critical patent/JP2014532759A5/ja
Application granted granted Critical
Publication of JP6047172B2 publication Critical patent/JP6047172B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014541012A 2011-11-04 2011-11-04 患者部分集団における痛風の治療方法 Expired - Fee Related JP6047172B2 (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2011/059425 WO2013066352A1 (en) 2011-11-04 2011-11-04 Methods for treating gout in patient subpopulations

Publications (3)

Publication Number Publication Date
JP2014532759A JP2014532759A (ja) 2014-12-08
JP2014532759A5 JP2014532759A5 (OSRAM) 2015-01-22
JP6047172B2 true JP6047172B2 (ja) 2016-12-21

Family

ID=48192536

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014541012A Expired - Fee Related JP6047172B2 (ja) 2011-11-04 2011-11-04 患者部分集団における痛風の治療方法

Country Status (14)

Country Link
EP (1) EP2775835A4 (OSRAM)
JP (1) JP6047172B2 (OSRAM)
KR (1) KR101848122B1 (OSRAM)
CN (1) CN104066323A (OSRAM)
AU (1) AU2011380509B2 (OSRAM)
BR (1) BR112014010693A2 (OSRAM)
CA (1) CA2859689C (OSRAM)
CL (1) CL2014001156A1 (OSRAM)
IL (1) IL232385A (OSRAM)
MX (1) MX354846B (OSRAM)
NZ (1) NZ624714A (OSRAM)
SG (1) SG11201402027PA (OSRAM)
WO (1) WO2013066352A1 (OSRAM)
ZA (1) ZA201403574B (OSRAM)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2836209A4 (en) * 2012-04-13 2015-11-25 Cymabay Therapeutics Inc METHOD FOR THE TREATMENT OF HYPERURICEMIA IN PATIENTS WITH A GOG THROUGH HALOFENATE OR HALOFENIC ACID AND AN INFLAMMATORY INHIBITOR
CN104068288B (zh) * 2014-07-25 2016-08-24 许伟琦 一种防尿路结石的饲料添加剂
CN105920022A (zh) * 2016-05-12 2016-09-07 成都易创思生物科技有限公司 一种抗痛风药物复方制剂
WO2019082335A1 (ja) * 2017-10-26 2019-05-02 大塚製薬株式会社 イノシトールリン酸含有組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4250191A (en) * 1978-11-30 1981-02-10 Edwards K David Preventing renal failure
US6262118B1 (en) * 1999-06-04 2001-07-17 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
CN103058944B (zh) * 2007-11-27 2015-08-05 亚德生化公司 调节血液尿酸水平的化合物

Also Published As

Publication number Publication date
EP2775835A1 (en) 2014-09-17
CN104066323A (zh) 2014-09-24
IL232385A (en) 2017-10-31
IL232385A0 (en) 2014-06-30
MX354846B (es) 2018-03-22
NZ624714A (en) 2016-01-29
CA2859689A1 (en) 2013-05-10
BR112014010693A2 (pt) 2020-11-10
CL2014001156A1 (es) 2015-01-16
ZA201403574B (en) 2015-11-25
KR101848122B1 (ko) 2018-04-11
KR20140123927A (ko) 2014-10-23
MX2014005399A (es) 2015-04-08
WO2013066352A1 (en) 2013-05-10
AU2011380509A1 (en) 2014-05-29
EP2775835A4 (en) 2015-07-29
CA2859689C (en) 2018-05-22
SG11201402027PA (en) 2014-09-26
JP2014532759A (ja) 2014-12-08
AU2011380509B2 (en) 2016-05-19

Similar Documents

Publication Publication Date Title
JP6008974B2 (ja) 痛風発赤の治療方法
US10137112B2 (en) Methods for treating hyperuricemia in patients with gout using halofenate or halofenic acid and a second urate-lowering agent
JP6202633B2 (ja) ハロフェナートまたはハロフェン酸および第２の尿酸低下薬を用いる痛風に罹っている患者の高尿酸血症の治療方法
JP6047172B2 (ja) 患者部分集団における痛風の治療方法
AU2013245675B2 (en) Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent
JP6368756B2 (ja) ハロフェナートまたはハロフェン酸および第２の尿酸低下薬を用いる痛風に罹っている患者の高尿酸血症の治療方法
US20130302305A1 (en) Methods for Treating Gout in Patients Subpopulations
JP6192142B2 (ja) 痛風発赤の治療方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141104

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141104

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150908

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160208

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20160218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160307

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160816

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160929

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20161025

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161118

R150 Certificate of patent or registration of utility model

Ref document number: 6047172

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313114

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees